After a strong start to the year, the Q2 performance was satisfactory. Acceleration in growth in the industrial applications and clinical microbiology businesses were the key highlights of the quarter. However, fierce competition weighed on the immunoassays division and the segment traded in the red during the quarter.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 performance satisfactory
After a strong start to the year, the Q2 performance was satisfactory. Acceleration in growth in the industrial applications and clinical microbiology businesses were the key highlights of the quarter. However, fierce competition weighed on the immunoassays division and the segment traded in the red during the quarter.